Proteomic Profiling Captures Residual Cardiovascular Risk Beyond the PREVENT Model in Individuals With Cardiovascular–Kidney–Metabolic Syndrome Stages 2–3
Performance · CVD risk, high vs low PRS (validation set)Result — go to the resultHazard ratio 2.56 95% CI 1.96–3.37Authors' conclusion
Combining the PREVENT model with the PRS developed in this study enhances the prediction of future CVD events in the CKM Stages 2-3 population.
Study context
- Population
- Participants with cardiovascular-kidney-metabolic (CKM) syndrome Stages 2–3 from the UK Biobankvalidation set n = 4799
- Participants
- 24,017 participants
- Comparison
- PREVENT model plus protein risk score (PRS) vs PREVENT model alone
- Outcome
- Incremental predictive performance of the cardiovascular disease (CVD) protein risk score over the PREVENT model (Harrell's C-statistic, NRI, IDI)
Methodological detailsUK Biobank cohort, training and validation sets, LASSO, Olink proteomics (2923 plasma proteins)
- UK Biobank cohort
- Training and validation sets
- LASSO
- Olink proteomics (2923 plasma proteins)
Performance
CVD risk, high vs low PRS (validation set)
Hazard ratio
2.56
95% CI 1.96–3.37
High PRSvs Low score
HR 2.56 (95% CI 1.96–3.37)
As reported in the abstract
- C-statistic improvement with PRS added to PREVENT (0.672-0.706)
- 0.034
- 10-year net reclassification improvement (NRI)
- 15.8% (95% CI: 9.5%-20.9%)
- Integrated discrimination improvement (IDI)
- 2.2% (95% CI: 1.3%-3.3%)
Further findings
PRS composition
- Proteins in risk score, mainly reflecting inflammation, kidney injury and matrix remodelling; key: GDF15, HAVCR1, MMP12, NT-proBNP
- 63
Original publication
Proteomic Profiling Captures Residual Cardiovascular Risk Beyond the PREVENT Model in Individuals With Cardiovascular–Kidney–Metabolic Syndrome Stages 2–3. Diabetes Obes Metab. Published 1 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →